Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free CTX Stock Alerts

Crescita Therapeutics (CTX) Competitors

Crescita Therapeutics logo
C$0.79 0.00 (0.00%)
As of 06/4/2026
Compare

CTX vs. HEXO, VIR, ZOM, META, and LABS

Should you buy Crescita Therapeutics stock or one of its competitors? MarketBeat compares Crescita Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Crescita Therapeutics include HEXO (HEXO), Viridium Pacific Group (VIR), Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM), Meta Growth (META), and MediPharm Labs (LABS). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does Crescita Therapeutics compare to HEXO?

HEXO (TSE:HEXO) and Crescita Therapeutics (TSE:CTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

7.6% of HEXO shares are held by institutional investors. Comparatively, 3.1% of Crescita Therapeutics shares are held by institutional investors. 3.0% of HEXO shares are held by company insiders. Comparatively, 10.9% of Crescita Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, HEXO's average media sentiment score of 0.00 equaled Crescita Therapeutics'average media sentiment score.

Company Overall Sentiment
HEXO Neutral
Crescita Therapeutics Neutral

HEXO has a beta of 2.13, indicating that its share price is 113% more volatile than the broader market. Comparatively, Crescita Therapeutics has a beta of -1.548718, indicating that its share price is 255% less volatile than the broader market.

Crescita Therapeutics has lower revenue, but higher earnings than HEXO. Crescita Therapeutics is trading at a lower price-to-earnings ratio than HEXO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HEXOC$124.10M0.00-C$273.18M-C$3.41N/A
Crescita TherapeuticsC$23.22M0.63-C$2.61M-C$0.01N/A

Crescita Therapeutics has a net margin of -1.38% compared to HEXO's net margin of -220.13%. Crescita Therapeutics' return on equity of -2.07% beat HEXO's return on equity.

Company Net Margins Return on Equity Return on Assets
HEXO-220.13% -106.39% -14.96%
Crescita Therapeutics -1.38%-2.07%-8.26%

Summary

Crescita Therapeutics beats HEXO on 6 of the 10 factors compared between the two stocks.

How does Crescita Therapeutics compare to Viridium Pacific Group?

Viridium Pacific Group (CVE:VIR) and Crescita Therapeutics (TSE:CTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Crescita Therapeutics has higher revenue and earnings than Viridium Pacific Group. Crescita Therapeutics is trading at a lower price-to-earnings ratio than Viridium Pacific Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridium Pacific GroupC$1.09M34.46-C$12.64M-C$0.13N/A
Crescita TherapeuticsC$23.22M0.63-C$2.61M-C$0.01N/A

In the previous week, Viridium Pacific Group's average media sentiment score of 0.00 equaled Crescita Therapeutics'average media sentiment score.

Company Overall Sentiment
Viridium Pacific Group Neutral
Crescita Therapeutics Neutral

3.1% of Crescita Therapeutics shares are owned by institutional investors. 10.9% of Crescita Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Viridium Pacific Group has a net margin of 0.00% compared to Crescita Therapeutics' net margin of -1.38%. Viridium Pacific Group's return on equity of 0.00% beat Crescita Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Viridium Pacific GroupN/A N/A N/A
Crescita Therapeutics -1.38%-2.07%-8.26%

Summary

Viridium Pacific Group and Crescita Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Crescita Therapeutics compare to Zomedica Pharmaceuticals Corp. (ZOM.V)?

Zomedica Pharmaceuticals Corp. (ZOM.V) (CVE:ZOM) and Crescita Therapeutics (TSE:CTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

Zomedica Pharmaceuticals Corp. (ZOM.V) has higher earnings, but lower revenue than Crescita Therapeutics. Crescita Therapeutics is trading at a lower price-to-earnings ratio than Zomedica Pharmaceuticals Corp. (ZOM.V), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zomedica Pharmaceuticals Corp. (ZOM.V)N/AN/AN/A-C$0.11N/A
Crescita TherapeuticsC$23.22M0.63-C$2.61M-C$0.01N/A

In the previous week, Zomedica Pharmaceuticals Corp. (ZOM.V)'s average media sentiment score of 0.00 equaled Crescita Therapeutics'average media sentiment score.

Company Overall Sentiment
Zomedica Pharmaceuticals Corp. (ZOM.V) Neutral
Crescita Therapeutics Neutral

Zomedica Pharmaceuticals Corp. (ZOM.V) has a net margin of 0.00% compared to Crescita Therapeutics' net margin of -1.38%. Zomedica Pharmaceuticals Corp. (ZOM.V)'s return on equity of 0.00% beat Crescita Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Zomedica Pharmaceuticals Corp. (ZOM.V)N/A N/A N/A
Crescita Therapeutics -1.38%-2.07%-8.26%

3.1% of Crescita Therapeutics shares are held by institutional investors. 10.9% of Crescita Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Zomedica Pharmaceuticals Corp. (ZOM.V) and Crescita Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Crescita Therapeutics compare to Meta Growth?

Meta Growth (CVE:META) and Crescita Therapeutics (TSE:CTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Meta Growth has a net margin of 0.00% compared to Crescita Therapeutics' net margin of -1.38%. Meta Growth's return on equity of 0.00% beat Crescita Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Meta GrowthN/A N/A N/A
Crescita Therapeutics -1.38%-2.07%-8.26%

3.1% of Crescita Therapeutics shares are owned by institutional investors. 10.9% of Crescita Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Crescita Therapeutics has lower revenue, but higher earnings than Meta Growth. Crescita Therapeutics is trading at a lower price-to-earnings ratio than Meta Growth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Meta GrowthC$60.96M0.54-C$50.41M-C$0.21N/A
Crescita TherapeuticsC$23.22M0.63-C$2.61M-C$0.01N/A

In the previous week, Meta Growth had 5 more articles in the media than Crescita Therapeutics. MarketBeat recorded 5 mentions for Meta Growth and 0 mentions for Crescita Therapeutics. Meta Growth's average media sentiment score of 0.40 beat Crescita Therapeutics' score of 0.00 indicating that Meta Growth is being referred to more favorably in the media.

Company Overall Sentiment
Meta Growth Neutral
Crescita Therapeutics Neutral

Summary

Meta Growth beats Crescita Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Crescita Therapeutics compare to MediPharm Labs?

MediPharm Labs (TSE:LABS) and Crescita Therapeutics (TSE:CTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Crescita Therapeutics has a net margin of -1.38% compared to MediPharm Labs' net margin of -20.21%. Crescita Therapeutics' return on equity of -2.07% beat MediPharm Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
MediPharm Labs-20.21% -23.55% -7.17%
Crescita Therapeutics -1.38%-2.07%-8.26%

MediPharm Labs has a beta of -0.614829, indicating that its stock price is 161% less volatile than the broader market. Comparatively, Crescita Therapeutics has a beta of -1.548718, indicating that its stock price is 255% less volatile than the broader market.

0.3% of MediPharm Labs shares are held by institutional investors. Comparatively, 3.1% of Crescita Therapeutics shares are held by institutional investors. 4.5% of MediPharm Labs shares are held by company insiders. Comparatively, 10.9% of Crescita Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Crescita Therapeutics has lower revenue, but higher earnings than MediPharm Labs. Crescita Therapeutics is trading at a lower price-to-earnings ratio than MediPharm Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediPharm LabsC$43.28M0.74-C$12.05M-C$0.02N/A
Crescita TherapeuticsC$23.22M0.63-C$2.61M-C$0.01N/A

In the previous week, MediPharm Labs had 2 more articles in the media than Crescita Therapeutics. MarketBeat recorded 2 mentions for MediPharm Labs and 0 mentions for Crescita Therapeutics. MediPharm Labs' average media sentiment score of 0.42 beat Crescita Therapeutics' score of 0.00 indicating that MediPharm Labs is being referred to more favorably in the media.

Company Overall Sentiment
MediPharm Labs Neutral
Crescita Therapeutics Neutral

Summary

MediPharm Labs beats Crescita Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Crescita Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CTX vs. The Competition

Export
MetricCrescita TherapeuticsDrug Manufacturers IndustryMedical SectorTSE Exchange
Market CapC$14.71MC$2.39BC$6.52BC$12.19B
Dividend YieldN/A2.94%2.67%6.19%
P/E Ratio-79.005.0224.0036.94
Price / Sales0.631,639.28516.4210.45
Price / Cash1.2010.1827.4882.29
Price / Book1.0210.4110.744.47
Net Income-C$2.61MC$20.27BC$3.57BC$299.09M
7 Day PerformanceN/A-0.99%0.58%0.65%
1 Month Performance3.95%5.83%1.48%-0.08%
1 Year PerformanceN/A15.90%25.41%41.90%

Crescita Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CTX
Crescita Therapeutics
N/AC$0.79
flat		N/AN/AC$14.71MC$23.22MN/A62
HEXO
HEXO
N/AN/AN/AN/AC$38.72MC$124.10MN/A690
VIR
Viridium Pacific Group
N/AC$0.38
+5.6%		N/A+0.0%C$37.52MC$1.09MN/A580
ZOM
Zomedica Pharmaceuticals Corp. (ZOM.V)
N/AC$0.29
-6.6%		N/A+0.0%C$36.73MN/AN/A50
META
Meta Growth
N/AC$0.14
flat		N/A+0.0%C$33.14MC$60.96MN/A86,500

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:CTX) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel